Eosinophilic gastroenteritis

H&E Stain: Dense Eosinophilic infiltration of gastro-duodenal wall
Specialty| Immunology, gastroenterology

Eosinophilic gastroenteritis (EG or EGE) is a heterogeneous condition characterized by patchy or diffuse eosinophilic infiltration of gastrointestinal (GI) tissue.[1][2] Symptoms vary depending on location and extent of bowel wall involvement and usually runs a chronic relapsing course.

It can be classified into mucosal, muscular and serosal types based on the depth of involvement.[3][4] Any part of the GI tract can be affected, and isolated biliary tract involvement has also been reported.[5][6] The stomach is the organ most commonly affected, followed by the small intestine and the colon.[7][8]

Eosinophilic gastroenteritis is a rare.[1] It was first described by Kaijser in 1937.[1]

## Contents

* 1 Signs and symptoms
* 2 Pathophysiology
* 3 Diagnosis
* 3.1 Differential diagnosis
* 4 Management
* 5 Epidemiology
* 6 See also
* 7 References
* 8 External links

## Signs and symptoms[edit | edit source]

EG typically presents with a combination of chronic nonspecific GI symptoms which include abdominal pain, diarrhea, occasional nausea and vomiting, weight loss and abdominal distension. Approximately 80% have symptoms for several years;[6] a high degree of clinical suspicion is often required to establish the diagnosis, as the disease is extremely rare. It doesn't come all of a sudden but takes about 3–4 years to develop depending upon the age of the patient. Occasionally, the disease may manifest itself as an acute abdomen or bowel obstruction.[9][10]

* Mucosal EG (25–100%) is the most common variety,[11][12] which presents with features of malabsorption and protein losing enteropathy. Failure to thrive and anaemia may also be present. Lower gastrointestinal bleeding may imply colonic involvement.
* Muscular EG (13–70%) present with obstruction of gastric outlet or small intestine; sometimes as an obstructing caecal mass or intussusception.
* Subserosal EG (4.5% to 9% in Japan and 13% in the US)[13] presents with ascites which is usually exudative in nature, abundant peripheral eosinophilia, and has favourable responses to corticosteroids.
* Other documented features are cholangitis, pancreatitis,[citation needed] eosinophilic splenitis, acute appendicitis and giant refractory duodenal ulcer.

## Pathophysiology[edit | edit source]

Peripheral blood eosinophilia and elevated serum IgE are usual but not universal. The damage to the gastrointestinal tract wall is caused by eosinophilic infiltration and degranulation.[14]

As a part of host defense mechanism, eosinophils are normally present in gastrointestinal mucosa, though the finding in deeper tissue is almost always pathologic.[15] What triggers such dense infiltration in EG is not clear. It is possible that different pathogenetic mechanisms of disease is involved in several subgroups of patients. Food allergy and variable IgE response to food substances has been observed in some patients which implies role of hypersensitive response in pathogenesis. Many patients indeed have history of other atopic conditions like eczema, asthma, etc.[citation needed]

Eosinophil recruitment into inflammatory tissue is a complex process, regulated by a number of inflammatory cytokines. In EG cytokines IL-3, IL-5 and granulocyte macrophage colony stimulating factor (GM-CSF) may be behind the recruitment and activation. They have been observed immunohistochemically in diseased intestinal wall.[16] In addition eotaxin has been shown to have an integral role in regulating the homing of eosinophils into the lamina propria of stomach and small intestine.[17] In the allergic subtype of disease, it is thought that food allergens cross the intestinal mucosa and trigger an inflammatory response that includes mast cell degranulation and recruitment of eosinophils.[17][18]

## Diagnosis[edit | edit source]

Talley et al.[19] suggested 3 diagnostic criteria which are still widely used:

1. the presence of gastrointestinal symptoms,
2. histological demonstration of eosinophilic infiltration in one or more areas of the gastrointestinal tract or presence of high eosinophil count in ascitic fluid (latter usually indicates subserosal variety),
3. no evidence of parasitic or extraintestinal disease.

Hypereosinophilia, the hallmark of allergic response, may be absent in up to 20% of patients, but hypoalbuminaemia and other abnormalities suggestive of malabsorption may be present. CT scans may show nodular and irregular thickening of the folds in the distal stomach and proximal small bowel, but these findings can also be present in other conditions like Crohn's disease and lymphoma.[citation needed]

The endoscopic appearance in eosinophilic gastroenteritis is nonspecific; it includes erythematous, friable, nodular, and occasional ulcerative changes.[20] Sometimes diffuse inflammation results in complete loss of villi, involvement of multiple layers, submucosal oedema and fibrosis.[21][22]

Definitive diagnosis involves histological evidence of eosinophilic infiltration in biopsy slides. Microscopy reveals >20 eosinophils per high power field.[11][19] Infiltration is often patchy, can be missed and laparoscopic full thickness biopsy may be required.

Radio isotope scan using technetium (99mTc) exametazime-labeled leukocyte SPECT may be useful in assessing the extent of disease and response to treatment but has little value in diagnosis, as the scan does not help differentiating EG from other causes of inflammation.[23][24]

When eosinophilic gastroenteritis is observed in association with eosinophilic infiltration of other organ systems, the diagnosis of idiopathic hypereosinophilic syndrome should be considered.[25]

* a,b)Endoscopic findings in an individual with eosinophilic gastroenteritis

* Spiral CT showing ascites and concentric thickening of colon and ileum in EG

### Differential diagnosis[edit | edit source]

* Eosinophilic esophagitis
* Eosinophilic ascites
* Coeliac disease
* Protein losing enteropathy from intolerance to cow's milk protein
* Infantile formula protein intolerance

## Management[edit | edit source]

Corticosteroids are the mainstay of therapy with a 90% response rate in some studies. Appropriate duration of steroid treatment is unknown and relapse often necessitates long term treatment. Various steroid sparing agents e.g. sodium cromoglycate (a stabilizer of mast cell membranes), ketotifen (an antihistamine), and montelukast (a selective, competitive leukotriene receptor antagonist) have been proposed, centering on an allergic hypothesis, with mixed results.[18][26] Oral budesonide (an oral steroid) can be useful in treatment, as well.[27] An elimination diet may be successful if a limited number of food allergies are identified.[20][28] An elemental diet may also be successful in the treatment of children.[29]

In a randomized clinical trial, lirentelimab was found to improve eosinophil counts and symptoms in individuals with eosinophilic gastritis and duodenitis.[30][31]

## Epidemiology[edit | edit source]

Epidemiology may differ between studies, as number of cases are small, with approximately 300 EG cases reported in published literature.

EG can present at any age and across all races, with a slightly higher incidence in males.[32] Earlier studies showed higher incidence in the third to fifth decades of life.[1][3]

## See also[edit | edit source]

* Aeroallergen
* Allergy
* Gastroenteritis
* Malabsorption

## References[edit | edit source]

1. ↑ 1.0 1.1 1.2 1.3 Kaijser R. Zur Kenntnis der allergischen Affektionen des Verdauugskanals vom Standpunkt des Chirurgen aus. Arch Klin Chir 1937; 188:36–64.
2. ↑ Whitaker I, Gulati A, McDaid J, Bugajska-Carr U, Arends M (2004). "Eosinophilic gastroenteritis presenting as obstructive jaundice". European Journal of Gastroenterology & Hepatology. 16 (4): 407–9. doi:10.1097/00042737-200404000-00007. PMID 15028974.
3. ↑ 3.0 3.1 Klein N, Hargrove R, Sleisenger M, Jeffries G (1970). "Eosinophilic gastroenteritis". Medicine (Baltimore). 49 (4): 299–319. doi:10.1097/00005792-197007000-00003. PMID 5426746. S2CID 45969740.
4. ↑ Treiber, Treiber; Weidner, S (2007). "Eosinophilic Gastroenteritis". Clinical Gastroenterology and Hepatology. 5 (5): e16. doi:10.1016/j.cgh.2007.01.011. PMID 17428742.
5. ↑ Polyak S, Smith T, Mertz H (2002). "Eosinophilic gastroenteritis causing pancreatitis and pancreaticobiliary ductal dilation". Dig. Dis. Sci. 47 (5): 1091–5. doi:10.1023/A:1015046309132. PMID 12018905. S2CID 24453648.
6. ↑ 6.0 6.1 Christopher V, Thompson M, Hughes S (2002). "Eosinophilic gastroenteritis mimicking pancreatic cancer". Postgraduate Medical Journal. 78 (922): 498–9. doi:10.1136/pmj.78.922.498. PMC 1742453. PMID 12185230.
7. ↑ Naylor A (1990). "Eosinophilic gastroenteritis". Scottish Medical Journal. 35 (6): 163–5. doi:10.1177/003693309003500601. PMID 2077646. S2CID 43539786.
8. ↑ Jimenez-Saenz M, Villar-Rodriguez J, Torres Y, Carmona I, Salas-Herrero E, Gonzalez-Vilches J, Herrerias-Gutierrez J (2003). "Biliary tract disease: a rare manifestation of eosinophilic gastroenteritis". Dig. Dis. Sci. 48 (3): 624–7. doi:10.1023/A:1022521707420. PMID 12757181. S2CID 23627059.
9. ↑ Shweiki E, West J, Klena J, Kelley S, Colley A, Bross R, Tyler W (1999). "Eosinophilic gastroenteritis presenting as an obstructing cecal mass--a case report and review of the literature". Am. J. Gastroenterol. 94 (12): 3644–5. PMID 10606337.
10. ↑ Tran D, Salloum L, Tshibaka C, Moser R (2000). "Eosinophilic gastroenteritis mimicking acute appendicitis". The American Surgeon. 66 (10): 990–2. PMID 11261632.
11. ↑ 11.0 11.1 Baig M, Qadir A, Rasheed J (2006). "A review of eosinophilic gastroenteritis". Journal of the National Medical Association. 98 (10): 1616–9. PMC 2569760. PMID 17052051.
12. ↑ Lee C, Changchien C, Chen P, Lin D, Sheen I, Wang C, Tai D, Sheen-Chen S, Chen W, Wu C (1993). "Eosinophilic gastroenteritis: 10 years experience". Am. J. Gastroenterol. 88 (1): 70–4. PMID 8420276.
13. ↑ Miyamoto T, Shibata T, Matsuura S, Kagesawa M, Ishizawa Y, Tamiya K (1996). "Eosinophilic gastroenteritis with ileus and ascites". Intern. Med. 35 (10): 779–82. doi:10.2169/internalmedicine.35.779. PMID 8933185.)
14. ↑ Tan A, Kruimel J, Naber T (2001). "Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets". European Journal of Gastroenterology & Hepatology. 13 (4): 425–7. doi:10.1097/00042737-200104000-00021. PMID 11338074.
15. ↑ Blackshaw A, Levison D (1986). "Eosinophilic infiltrates of the gastrointestinal tract". J. Clin. Pathol. 39 (1): 1–7. doi:10.1136/jcp.39.1.1. PMC 499605. PMID 2869055.
16. ↑ Desreumaux P, Bloget F, Seguy D, Capron M, Cortot A, Colombel J, Janin A (1996). "Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis". Gastroenterology. 110 (3): 768–74. doi:10.1053/gast.1996.v110.pm8608886. PMID 8608886.
17. ↑ 17.0 17.1 Mishra A, Hogan S, Brandt E, Rothenberg M (2001). "An etiological role for aeroallergens and eosinophils in experimental esophagitis". J. Clin. Invest. 107 (1): 83–90. doi:10.1172/JCI10224. PMC 198543. PMID 11134183.
18. ↑ 18.0 18.1 Pérez-Millán A, Martín-Lorente J, López-Morante A, Yuguero L, Sáez-Royuela F (1997). "Subserosal eosinophilic gastroenteritis treated efficaciously with sodium cromoglycate". Dig. Dis. Sci. 42 (2): 342–4. doi:10.1023/A:1018818003002. PMID 9052516. S2CID 19266537.
19. ↑ 19.0 19.1 Talley N, Shorter R, Phillips S, Zinsmeister A (1990). "Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues". Gut. 31 (1): 54–8. doi:10.1136/gut.31.1.54. PMC 1378340. PMID 2318432.
20. ↑ 20.0 20.1 Chen M, Chu C, Lin S, Shih S, Wang T (2003). "Eosinophilic gastroenteritis: clinical experience with 15 patients". World J. Gastroenterol. 9 (12): 2813–6. doi:10.3748/wjg.v9.i12.2813. PMC 4612059. PMID 14669340.
21. ↑ Johnstone J, Morson B (1978). "Eosinophilic gastroenteritis". Histopathology. 2 (5): 335–48. doi:10.1111/j.1365-2559.1978.tb01726.x. PMID 363591.
22. ↑ Katz A, Goldman H, Grand R (1977). "Gastric mucosal biopsy in eosinophilic (allergic) gastroenteritis". Gastroenterology. 73 (4 Pt 1): 705–9. doi:10.1016/S0016-5085(19)31769-X. PMID 892374.
23. ↑ Lee K, Hahm K, Kim Y, Kim J, Cho S, Jie H, Park C, Yim H (1997). "The usefulness of Tc-99m HMPAO labeled WBC SPECT in eosinophilic gastroenteritis". Clinical Nuclear Medicine. 22 (8): 536–41. doi:10.1097/00003072-199708000-00005. PMID 9262899.
24. ↑ Imai E, Kaminaga T, Kawasugi K, Yokokawa T, Furui S (2003). "The usefulness of 99mTc-hexamethylpropyleneamineoxime white blood cell scintigraphy in a patient with eosinophilic gastroenteritis". Annals of Nuclear Medicine. 17 (7): 601–3. doi:10.1007/BF03006675. PMID 14651361. S2CID 32498521.
25. ↑ Matsushita M, Hajiro K, Morita Y, Takakuwa H, Suzaki T (1995). "Eosinophilic gastroenteritis involving the entire digestive tract". Am. J. Gastroenterol. 90 (10): 1868–70. PMID 7572911.
26. ↑ Barbie D, Mangi A, Lauwers G (2004). "Eosinophilic gastroenteritis associated with systemic lupus erythematosus". J. Clin. Gastroenterol. 38 (10): 883–6. doi:10.1097/00004836-200411000-00010. PMID 15492606.
27. ↑ Alsayegh, Mohammad; Mack, Douglas (2012-11-02). "Eosinophilic gastroenteritis with gastric and small bowel involvement: successful treatment with oral budesonide". Allergy, Asthma, and Clinical Immunology. 8 (Suppl 1): A6. doi:10.1186/1710-1492-8-S1-A6. ISSN 1710-1484. PMC 3487875.
28. ↑ Katz A, Twarog F, Zeiger R, Falchuk Z (1984). "Milk-sensitive and eosinophilic gastroenteropathy: similar clinical features with contrasting mechanisms and clinical course". The Journal of Allergy and Clinical Immunology. 74 (1): 72–8. doi:10.1016/0091-6749(84)90090-3. PMID 6547462.
29. ↑ Lucendo, Alfredo J.; Serrano-Montalbán, Beatriz; Arias, Ángel; Redondo, Olga; Tenias, José M. (July 2015). "Efficacy of Dietary Treatment for Inducing Disease Remission in Eosinophilic Gastroenteritis". Journal of Pediatric Gastroenterology and Nutrition. 61 (1): 56–64. doi:10.1097/MPG.0000000000000766. ISSN 0277-2116. Archived from the original on 2023-01-18. Retrieved 2022-11-13.
30. ↑ Dellon, ES; Peterson, KA; Murray, JA; Falk, GW; Gonsalves, N; Chehade, M; Genta, RM; Leung, J; Khoury, P; Klion, AD; Hazan, S; Vaezi, M; Bledsoe, AC; Durrani, SR; Wang, C; Shaw, C; Chang, AT; Singh, B; Kamboj, AP; Rasmussen, HS; Rothenberg, ME; Hirano, I (22 October 2020). "Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis". The New England Journal of Medicine. 383 (17): 1624–1634. doi:10.1056/NEJMoa2012047. PMC 7600443. PMID 33085861.
31. ↑ Young, Alex (October 29, 2019). "Therapeutic antibody effective in eosinophilic gastritis". Healio. Archived from the original on 18 January 2023. Retrieved 14 December 2020.
32. ↑ Guandalini, Stefano (2004). Essential Pediatric Gastroenterology and Nutrition. City: McGraw-Hill Professional. ISBN 978-0-07-141630-6. Page 210.

## External links[edit | edit source]

Classification|

* ICD-10: K52.8
* ICD-9-CM: 558.3
* DiseasesDB: 32555

|

External resources|

* eMedicine: med/688

* v
* t
* e

Allergic conditions

Respiratory system|

* Allergic rhinitis (hay fever)
* Asthma
* Hypersensitivity pneumonitis
* Eosinophilic pneumonia
* Eosinophilic granulomatosis with polyangiitis
* Allergic bronchopulmonary aspergillosis
* Farmer's lung
* Laboratory animal allergy

Skin|

* Angioedema
* Urticaria
* Atopic dermatitis
* Allergic contact dermatitis
* Hypersensitivity vasculitis

Blood and immune system|

* Serum sickness

Circulatory system|

* Anaphylaxis

Digestive system|

* Coeliac disease
* Eosinophilic gastroenteritis
* Eosinophilic esophagitis
* Food allergy
* Egg allergy
* Milk intolerance

Nervous system|

* Eosinophilic meningitis

Genitourinary system|

* Acute interstitial nephritis

Other conditions|

* Drug allergy
* Allergic conjunctivitis
* Latex allergy

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template